Summary:
A multicenter, randomized, double-blind, active and placebo-controlled study to evaluate the efficacy and safety of Arhalofenate for preventing flares and reducing serum uric acid in gout patients.
Qualified Participants Must:
• Be between 18 and 75 years of age
•
Have been diagnosed with Gout
•
Have had at least 3 flares in the last year
•
Not currently be taking Gout medication
Qualified Participants May Receive:
Study Gout medication, study labs and exams and compensation for time and travel.